Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Combined With CAR-T Therapy in High-Risk Relapsed/Refractory Large B-Cell Lymphoma
NCT07326371Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2026
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07326371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07326371.